NCT07279259RecruitingPhase 2
Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management
Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management, EAST-BP
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 340 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 15 Jan 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Shanghai East Hospital
- Diseases
- Stroke
- NCT number
- NCT07279259
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 340
- From 15 Jan 2026 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intracranial or spinal surgery within the last 3 months; major surgery within the last 2 weeks; arterial puncture at a site not easily compressed for hemostasis within the last 7 days.
- Currently participating in other drug or device clinical trials
Other illness
- Intracranial hemorrhage is indicated on CT or MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma).
- History of intracranial hemorrhage; severe head trauma or stroke within the last 3 months.
- Gastrointestinal or urinary system bleeding within the last 3 weeks.
- Active visceral hemorrhage, known bleeding diathesis or significant bleeding disorders within the past 6 months
- Severe ischemic stroke (NIHSS score \> 25)
- Epileptic seizures at the time of stroke onset
- Various terminal diseases with an expected survival of ≤ 3 months
- Any other physical conditions where the doctor deems participation in this study may be detrimental to the patient
- mRS score \> 2 before onset of the disease.
Lab values
- Acute bleeding tendency, including platelet count \< 100×10\^9/L or other bleeding tendencies.
- Received low-molecular-weight heparin orally within 24 hours; taking warfarin with INR \> 1.7 or PT \> 15 seconds; used a new oral anticoagulant within 48 hours.
- Blood glucose \< 2.8 mmol/L or \> 22.2 mmol/L.
Other
- Intracranial tumors, giant intracranial aneurysms.
- Aortic dissection.
- Large area cerebral infarction indicated on head CT or MRI (infarction area \> 1/3 of the middle cerebral artery territory).
- Pregnant or lactating women
Who the study is looking for
- Age 18 to 80 years (inclusive);
- Patients with acute ischemic stroke;
- Planned to receive intravenous thrombolysis within 4.5 hours of onset;
- Elevated blood pressure: Before receiving intravenous thrombolysis treatment, blood pressure is elevated: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg (defined as two consecutive measurements within 2 minutes);
- Informed consent signed (or signed by a proxy).
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai East Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.